Search

Alexander Sulakvelidze's team at Intralytix announced U.S. patent allowance for Campylobacter phages, showing strengthened intellectual property protection for CampyShield™, an FDA GRAS-affirmed antimicrobial preparation targeting foodborne

Pherecydes has a new phage therapy patent. It covers new S. aureus phages and their manufacture and combination for use in phage therapy and as a companion diagnostic.

Intralytix, Inc. has been issued a patent by the European Patent Office for several Shigella phages and their applications and formulations.